1. Home
  2. FLGT vs AUTL Comparison

FLGT vs AUTL Comparison

Compare FLGT & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fulgent Genetics Inc.

FLGT

Fulgent Genetics Inc.

N/A

Current Price

$21.63

Market Cap

511.0M

Sector

Health Care

ML Signal

N/A

Logo Autolus Therapeutics plc

AUTL

Autolus Therapeutics plc

N/A

Current Price

$1.81

Market Cap

596.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FLGT
AUTL
Founded
2011
2014
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
511.0M
596.2M
IPO Year
2016
2025

Fundamental Metrics

Financial Performance
Metric
FLGT
AUTL
Price
$21.63
$1.81
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
★ $8.73
AVG Volume (30 Days)
286.8K
★ 1.4M
Earning Date
11-06-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
★ $18,730,000.00
$10,120,000.00
Revenue This Year
$2.80
$98.68
Revenue Next Year
$15.38
$28.47
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 496.00
52 Week Low
$13.46
$1.18
52 Week High
$31.04
$2.58

Technical Indicators

Market Signals
Indicator
FLGT
AUTL
Relative Strength Index (RSI) 54.75 41.97
Support Level $19.12 $1.37
Resistance Level $23.83 $1.92
Average True Range (ATR) 0.86 0.09
MACD -0.15 -0.01
Stochastic Oscillator 60.98 25.00

Price Performance

Historical Comparison
FLGT
AUTL

About FLGT Fulgent Genetics Inc.

Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.

About AUTL Autolus Therapeutics plc

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.

Share on Social Networks: